VolitionRx Reports 112% Revenue Growth, Advances Sepsis and Cancer Diagnostics
Event summary
- VolitionRx reported $1.4M in H1 2026 revenue, up 112% YoY.
- Nu.Q® NETs assay validated as an independent predictor of sepsis mortality in peer-reviewed studies.
- Feline lymphoma test manuscript submitted, triggering a $5M milestone payment.
- Active licensing discussions with over a dozen global diagnostic leaders.
- Capture-Seq™ platform detected over 95% of Stage I and II cancers in validation cohort.
The big picture
VolitionRx's strong H1 2026 performance underscores its multi-pillar strategy in diagnostics, spanning sepsis, cancer, and veterinary markets. The company's progress in clinical validation and commercial partnerships positions it to capitalize on a $27B+ addressable market, though execution risks remain in securing large-scale licensing deals and regulatory approvals. The shift toward point-of-care testing, particularly with its finger-prick sepsis assay, could significantly expand its market reach.
What we're watching
- Regulatory Progress
- Whether VolitionRx can secure conditional reimbursement for lung cancer tests in France by year-end 2026.
- Licensing Momentum
- The pace at which VolitionRx converts active licensing discussions into formal agreements with diagnostic leaders.
- Technical Validation
- How the Capture-Seq™ platform performs in larger clinical cohorts, which could unlock its $23B TAM potential.
Related topics